Nasdaq:AIRS
Airsculpt Technologies, Inc.
AIRS is a global innovator in body sculpting devices and surgical tools driving growth in the aesthetic medicine sector.
Key Metrics
Investment Thesis
Bull Case
The company's consistent positive operating cash flow and revenue expansion suggest underlying business strength that could support future profitability once fixed costs are covered. Proprietary technology with high barriers to entry in the aesthetic medicine space offers potential for market share growth as global demand for non-invasive body contouring procedures accelerates.
Bear Case
Persistent net losses and a substantial retained earnings deficit raise concerns about the company's ability to sustain operations without significant external capital or strategic restructuring. High debt levels including $65.5M in long-term debt combined with negative operating profit create financial leverage risks that could be exacerbated by any downturn in elective medical procedure volumes.
About Airsculpt Technologies, Inc.
Airsculpt Technologies, Inc. is a leading designer and manufacturer of medical-grade body contouring devices and surgical tools serving the aesthetic medicine and plastic surgery markets globally. The company leverages proprietary technology to offer non-invasive fat reduction solutions alongside innovative surgical instruments for healthcare professionals. With strong revenue growth in recent years, AIRS positions itself as a key enabler for the expanding aesthetic medicine industry.
Analysis
Management Discussion
While revenue grew from $168.8M in 2022 to $195.9M in 2023 before settling at $180.3M in 2024, the company continues to report net losses of $8.3M in the latest period. Cash flow from operations remains positive at $11.3M providing liquidity despite the net change in cash being negative due to substantial investing outflows of $14.0M for capital expenditures.
Industry Overview
The global aesthetic medicine industry is experiencing robust expansion driven by increasing consumer demand for minimally invasive body contouring solutions and aging demographics seeking non-surgical alternatives to traditional plastic surgery. This growth environment benefits established players with innovative product portfolios who can capture market share from emerging competitors in this high-value medical device sector.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $168.8M | $195.9M | $180.3M |
| Cost of Revenue | $62.8M | $74.0M | $71.4M |
| Gross Profit | $106.0M | $121.9M | $109.0M |
| Operating Expenses | $110.6M | $112.4M | $110.8M |
| Operating Income | $-4.5M | $9.5M | $-1.8M |
| G&A | $101.4M | $102.4M | $98.9M |
| Stock-Based Comp | $29.5M | $18.2M | $3.8M |
| D&A | $8.1M | $10.3M | $11.9M |
| Depreciation | $3.3M | $5.5M | $7.1M |
| Amortization | $4.8M | $4.8M | $4.8M |
| Other OpEx | $9.1M | $10.0M | $11.9M |
| Non-Operating Income | $-6.8M | $-6.5M | $-6.2M |
| Interest Expense | $6.8M | $6.5M | — |
| Pre-Tax Income | $-11.3M | $3.0M | $-8.1M |
| Income Tax | $3.4M | $7.5M | $188.0K |
| Continuing Ops | $-14.7M | $-4.5M | $-8.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-14.7M | $-4.5M | $-8.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-14.7M | $-4.5M | $-8.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $16.7M | $16.0M | $17.1M |
| Cash & Equivalents | $9.6M | $10.3M | $8.2M |
| Prepaid Expenses | $4.2M | $3.8M | $5.8M |
| Other Current Assets | $2.8M | $1.9M | $3.1M |
| Long-Term Assets | $184.1M | $188.1M | $192.9M |
| PP&E (Net) | $24.2M | $28.9M | $37.5M |
| Goodwill | $81.7M | $81.7M | $81.7M |
| Operating Leases | $23.8M | $25.4M | $25.7M |
| Other LT Assets | $54.4M | $52.0M | $48.0M |
| Total Assets | $200.8M | $204.0M | $210.0M |
| Current Liabilities | $22.3M | $20.3M | $28.6M |
| Accounts Payable | $3.8M | $3.9M | $6.3M |
| Current Debt | $2.1M | $2.1M | $4.2M |
| Current Leases | $4.4M | $5.4M | $6.1M |
| Deferred Revenue | $2.4M | $1.5M | $1.2M |
| Other Current Liab | $2.5M | $3.8M | $2.5M |
| Long-Term Liabilities | $107.7M | $99.7M | $102.1M |
| Long-Term Debt | $81.4M | $69.5M | $65.5M |
| LT Operating Leases | $19.7M | $22.7M | $24.2M |
| Other LT Liab | $6.5M | $7.5M | $12.4M |
| Total Liabilities | $130.0M | $120.0M | $130.7M |
| Shareholders' Equity | $70.8M | $84.0M | $79.3M |
| Paid-In Capital | $85.9M | $103.9M | $107.7M |
| Retained Earnings | $-15.1M | $-19.6M | $-27.8M |
| AOCI | $-76.0K | $-412.0K | $-687.0K |
| Total L&E | $200.8M | $204.0M | $210.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-14.7M | $-4.5M | $-8.3M |
| Non-Cash Adjustments | $20.4M | $24.9M | $7.4M |
| Working Capital Changes | $18.7M | $3.5M | $12.2M |
| Cash from Operations | $24.4M | $24.0M | $11.3M |
| Capital Expenditures | $12.9M | $9.9M | $14.0M |
| Cash from Investing | $-12.9M | $-9.9M | $-14.0M |
| Dividends Paid | $23.2M | $385.0K | $252.0K |
| Cash from Financing | $-27.3M | $-13.4M | $630.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-15.7M | $646.0K | $-2.0M |
| Beginning Cash | $25.3M | $9.6M | $10.3M |
| Ending Cash | $9.6M | $10.3M | $8.2M |
Frequently Asked Questions
How does Airsculpt Technologies, Inc. make money?
The company's financials reflect diverse revenue streams primarily driven by its proprietary non-invasive body contouring technologies, advanced surgical instrument manufacturing, and related medical device sales to hospitals and outpatient clinics worldwide.
What are the main risks for AIRS?
Investors should consider the significant accumulated retained earnings deficit of $27.8M indicating historical profitability challenges, high total liabilities relative to equity at 165%, potential regulatory hurdles in medical device markets, and volatility in global demand for elective aesthetic procedures.
What is AIRS's competitive advantage?
AIRS benefits from a robust portfolio of patented medical devices that provide unique clinical efficacy, strong brand recognition among aesthetic practitioners, and a diversified product mix that reduces reliance on any single revenue stream.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.